Sprint Bioscience AB (publ) reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was SEK 50.49 million compared to SEK 0.083 million a year ago. Revenue was SEK 54.32 million compared to SEK 0.447 million a year ago.

Net loss was SEK 0.438 million compared to SEK 60.17 million a year ago. Basic loss per share from continuing operations was SEK 0.01 compared to SEK 1.43 a year ago.